649736-30-1 Usage
Uses
Used in Medicinal Chemistry:
2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl)propan-2-ol is used as a chemical entity for the development of new pharmaceuticals, leveraging its structural features and potential biological activities. Its indol and triazine components may contribute to interactions with biological targets, offering opportunities for the treatment of various diseases.
Used in Drug Development:
In the pharmaceutical industry, 2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl)propan-2-ol is utilized as a starting point for the synthesis of novel drug candidates. Its unique molecular architecture may enable the design of compounds with specific therapeutic effects, targeting a range of medical conditions.
Note: Since the provided materials do not specify particular applications or industries for 2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl)propan-2-ol, the uses listed are general and based on the potential of its structural features in medicinal chemistry and drug development. Further research would be necessary to identify specific applications and industries where 2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yl)propan-2-ol could be effectively utilized.
Check Digit Verification of cas no
The CAS Registry Mumber 649736-30-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,4,9,7,3 and 6 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 649736-30:
(8*6)+(7*4)+(6*9)+(5*7)+(4*3)+(3*6)+(2*3)+(1*0)=201
201 % 10 = 1
So 649736-30-1 is a valid CAS Registry Number.
649736-30-1Relevant academic research and scientific papers
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol- 5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl) 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth
Cai, Zhen-Wei,Zhang, Yongzheng,Borzilleri, Robert M.,Qian, Ligang,Barbosa, Stephanie,Wei, Donna,Zheng, Xiaoping,Wu, Lawrence,Fan, Junying,Shi, Zhongping,Wautlet, Barri S.,Mortillo, Steve,Jeyaseelan Sr., Robert,Kukral, Daniel W.,Kamath, Amrita,Marathe, Punit,D'Arienzo, Celia,Derbin, George,Barrish, Joel C.,Robl, Jeffrey A.,Hunt, John T.,Lombardo, Louis J.,Fargnoli, Joseph,Bhide, Rajeev S.
, p. 1976 - 1980 (2008/12/22)
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability t
PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS
-
Page 31; 32, (2008/06/13)
The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
